Experience

Axantia

• Jordan
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Professional Medical Representative

  • Mar 2022 - Present



Mundipharma

• Pharmaceutical Manufacturing
• 700 & Above Employee

• Product Specialist

  • Feb 2019 - Mar 2022

  - Product Specialist on Specialty & Consumer line, covering the glaucoma portfolio line (Cosopt, Trusopt & Saflutan ) in South Jordan aligned with the newly launched asthma medication (Flutiform Inhaler) & covering the consumer portfolio line (Betadine Brand). (Jan 2020-Present) - Associate Product Specialist on Specialty line, covering the glaucoma portfolio line (Saflutan, Cosopt & Trusopt) aligned with the newly launched asthma medication (Flutiform). (March 2019 -Jan 2020) - Product Specialist on Specialty & Consumer line, covering the glaucoma portfolio line (Cosopt, Trusopt & Saflutan ) in South Jordan aligned with the newly launched asthma medication (Flutiform Inhaler) & covering the consumer portfolio line (Betadine Brand). (Jan 2020-Present) - Associate Product Specialist on Specialty line, covering the glaucoma portfolio line (Saflutan, Cosopt & Trusopt) aligned with the newly launched asthma medication (Flutiform). (March 2019 -Jan 2020)



MS PHARMA

• Jordan
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Medical Representative

  • Sep 2017 - Oct 2018

  - Primary Care (Sep 2017-July 2018), hospital line representative, covering the antibiotic portfolio line the major accounts in Jordan, aligned with Osteoporosis therapeutic area. - Oncology Line (Aug 2018- Oct 2018), After 11 months in the primary care line and after some great achievement within my allocated accounts, I moved to the oncology line, which is one of the organization’s main focus. - Primary Care (Sep 2017-July 2018), hospital line representative, covering the antibiotic portfolio line the major accounts in Jordan, aligned with Osteoporosis therapeutic area. - Oncology Line (Aug 2018- Oct 2018), After 11 months in the primary care line and after some great achievement within my allocated accounts, I moved to the oncology line, which is one of the organization’s main focus.